BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 15.4//EN
BEGIN:VTIMEZONE
TZID:Central Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Central Standard Time
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Central Daylight Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Plan Year 2027 (PY27) Maximum Fair Price (MFP) negotiations und
 er the Inflation Reduction Act unfolded against the backdrop of Trump-era 
 Most Favored Nation (MFN) executive orders and a volatile Part D market. F
 inal MFPs are set\, and CMS has published the methodology behind them. Thi
 s webinar decodes what those prices reveal about the current administratio
 n’s drug-pricing trajectory\, manufacturer margin outlook and pipeline ris
 k\, and the stability of Part D premiums and formularies. We’ll connect th
 erapeutic-class patterns and comparator choices to likely plan behavior—ti
 ering\, utilization management (UM)\, and benefit-channel steering—and nea
 r-term contracting dynamics. Walk away from this CCA healthcare series web
 inar with a concise playbook for how PY27 MFPs will shape 2026–2028 strate
 gy for payers and manufacturers.\nPlan Year 2027 (PY27) Maximum Fair Price
  (MFP) negotiations under the Inflation Reduction Act unfolded against the
  backdrop of Trump-era Most Favored Nation (MFN) executive orders and a vo
 latile Part D market. Final MFPs are set\, and CMS has published the metho
 dology behind them. This webinar decodes what those prices reveal about th
 e current administration’s drug-pricing trajectory\, manufacturer margin o
 utlook and pipeline risk\, and the stability of Part D premiums and formul
 aries. We’ll connect therapeutic-class patterns and comparator choices to 
 likely plan behavior—tiering\, utilization management (UM)\, and benefit-c
 hannel steering—and near-term contracting dynamics. Walk away from this CC
 A healthcare series webinar with a concise playbook for how PY27 MFPs will
  shape 2026–2028 strategy for payers and manufacturers.
DTEND:20260805T174500Z
DTSTAMP:20260624T121944Z
DTSTART:20260805T163000Z
LOCATION:
SEQUENCE:0
SUMMARY:Insights into Plan Year 2027: Maximum Fair Price for Prescription D
 rugs
UID:RFCALITEM639178859849379739
X-ALT-DESC;FMTTYPE=text/html:Plan Year 2027 (PY27) Maximum Fair Price (MFP)
  negotiations under the Inflation Reduction Act unfolded against the backd
 rop of Trump-era Most Favored Nation (MFN) executive orders and a volatile
  Part D market. Final MFPs are set\, and CMS has published the methodology
  behind them. This webinar decodes what those prices reveal about the curr
 ent administration’s drug-pricing trajectory\, manufacturer margin outlook
  and pipeline risk\, and the stability of Part D premiums and formularies.
  We’ll connect therapeutic-class patterns and comparator choices to likely
  plan behavior—tiering\, utilization management (UM)\, and benefit-channel
  steering—and near-term contracting dynamics. Walk away from this CCA heal
 thcare series webinar with a concise playbook for how PY27 MFPs will shape
  2026–2028 strategy for payers and manufacturers.\nPlan Year 2027 (PY27) M
 aximum Fair Price (MFP) negotiations under the Inflation Reduction Act unf
 olded against the backdrop of Trump-era Most Favored Nation (MFN) executiv
 e orders and a volatile Part D market. Final MFPs are set\, and CMS has pu
 blished the methodology behind them. This webinar decodes what those price
 s reveal about the current administration’s drug-pricing trajectory\, manu
 facturer margin outlook and pipeline risk\, and the stability of Part D pr
 emiums and formularies. We’ll connect therapeutic-class patterns and compa
 rator choices to likely plan behavior—tiering\, utilization management (UM
 )\, and benefit-channel steering—and near-term contracting dynamics. Walk 
 away from this CCA healthcare series webinar with a concise playbook for h
 ow PY27 MFPs will shape 2026–2028 strategy for payers and manufacturers.
END:VEVENT
END:VCALENDAR